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ABSTRACT
PROVIDER BASED INTERVENTIONS TO MITIGATE RISK FOR
OPIOID PAIN MEDICATION ABUSE AMONG ADULT
PATIENTS IN A PRIMARY CARE SETTING
by Sheree Lamara Conley-Donaldson
May 2017
Mental and substance use disorders are predicted to exceed all physical disease
processes causing major disability by 2020. Misuse and overdose of opioid pain
medications is a significant public health concern in the United States. Approximately 1
in 4 patients receiving prescription opioids in primary care settings struggle with misuse.
Half of all opioid prescriptions are written by primary care providers, including nurse
practitioners. The purpose of this DNP project was to determine if nurse practitioner
providers are implementing evidence-based practice guidelines including screening, brief
intervention, and referral to treatment (SBIRT) to mitigate risk of prescription opioid pain
medication misuse and abuse among patients who request a prescription for opioid pain
medication. Nurse practitioner providers were instructed on current evidence-based
opioid guidelines to include conducting a comprehensive assessment and screening for
opioid misuse/abuse, brief intervention, and referral for behavioral health/addiction
services treatment based on risk level scoring. There was a total of 9 out of 12 or 75% of
patients age 18-25 that presented requesting an opioid pain medication. There was an
even sex distribution, including 6 males (50%) and 6 females (50%). After implementing
screening, brief intervention, and treatment, eight (66%) patients were identified as low
risk; two (17%) patients were identified as moderate risk, and 2 (17%) patients were
ii

identified as high risk for opioid abuse. The two (17%) patients identified as high risk
received brief intervention and were referred for treatment. This project identified the risk
level for opioid pain medication misuse/abuse. Implementing evidence-based guidelines
for prescribing opioid pain medications and SBIRT in the clinical setting conjunctly with
other validated screening tools could prove to be quite effective in combating
misuse/abuse of opioid pain medication based on results of the project.
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CHAPTER I - INTRODUCTION
Mental and substance use disorders are predicted to exceed all physical disease
processes causing major disability by 2020 (Crowley & Kirschner, 2015). A drastic
increase in prevalence of opioid use disorder (OUD) has been linked to an increase in
opioid pain medication prescriptions (Centers for Disease Control and Prevention [CDC],
2016). In 2013, 249 million prescriptions for opioids were written by healthcare
providers to treat chronic pain (CDC, 2016). Individuals that are prescribed opioids for
chronic pain are at risk for misuse, abuse, addiction, overdose, and death if they take
opioid pain medications for nonmedical reasons (Katz, El-Gabalawy, Keyes, Martins, &
Sareen, 2013). Nonmedical prescription opioid use (NMPOU) leads to adverse health
outcomes and has thereby become a major public health concern (CDC, 2016). There are
mental and physical factors which may be used to predict OUD. Researchers found
prevalence of OUD in patients with comorbid mental disorders and physical conditions
(Katz et al., 2013).
Patients at risk for misuse and overdose of prescription opioid pain medications
frequent primary care settings. Half of all opioid prescriptions are written by primary care
providers, including nurse practitioners. Safe prescribing practice models for chronic
pain management have been developed for prescribing opioids (CDC, 2016; Hudspeth,
2016a; Hudspeth, 2016b). Approximately one in four patients receiving prescription
opioid pain medications in primary care settings struggle with misuse. Routine screening
for anxiety/depression and substance use disorders in primary care settings is imperative
to mitigate the risk for adverse health outcomes (CDC, 2016). This project focuses on
identification and prevention of opioid use disorder, through screening and referral for
1

treatment, in patients requesting a prescription opioid pain medication in a primary care
clinic.
Background
Misuse and overdose of opioid pain medications is a major public health concern
in the United States (U.S.). Approximately 1 in 4 patients receiving prescription opioids
in primary care settings struggle with misuse of opioid pain medication. More than 40
people die from prescription opioid overdoses per day (CDC, 2016). Greater than
165,000 deaths from overdose related to prescription opioids have occurred since 1999
and more than 14,000 individuals died in 2014 alone (CDC, 2016).
Significance
Cost of Opioid Misuse
Misuse and abuse of prescription pain medication alone has cost the nation around
$53.4 billion annually in lost productivity, medical costs, and criminal justice costs.
Health care dollars are being allocated for prevention and treatment of opioid use
disorder. Reimbursement will be determined by implementing new measures including
tracking of high-dose opioid use from four or more providers and pharmacies by noncancer patients using the prescription monitoring program (PMP) (CMS, 2015).
Medicare uses PMP to track opioid prescribers. A new strategy is being developed to
report physicians who may be prescribing opioids inappropriately. Centers for Medicare
and Medicaid Services (CMS) has launched an attack on the opioid epidemic (CMS,
2017a). The Medicare population has the one of the highest and fastest growing rates of
OUD. This is concluded to be due to no systemic policy of screening for opioid misuse.
State and national initiatives related to healthcare quality and cost include exploring the
2

possibility of supporting and strengthening primary care in efforts to improve quality and
reduce costs. The CMS strategy includes four priority areas. Prescribers are advised to
(1) implement more effective person-centered strategies to reduce risk of misuse and (2)
expand screening, diagnosis, and treatment of OUD. Practitioners are also encouraged to
(3) increase the use of evidence-based practices for acute and chronic pain management.
Improper prescribing is a contributory factor to misuse and overdose of opioid pain
medications; (4) naloxone use, distribute, and access should be expanded when clinically
necessary (CMS, 2017a).
Governmental agencies are combining forces to combat the problem of opioid
prescription drug overdose. The aim is to prevent misuse, treat dependence and
ultimately save lives. The extent of the problem has progressed from local and regional
perspectives to a national awareness. The United States Food and Drug Administration
(FDA) (2012) has joined the effort to decrease prescription opioid misuse. Public health
officials are collaborating with prescribers, state and local partners to ensure safe use and
disposal of opioid medications. In February 2016, the FDA received a citizen petition
from several local and state public health officials in addition to other stakeholders
requesting changes to existing labeling for opioid analgesics. The FDA supports stronger
warning labels and misuse deterrents (FDA, 2016). Opioid warning labels require boxed
warnings, which are the FDA’s strongest warning. The labels note that opioids carry
serious risks of misuse and abuse, addiction, overdose and even death (CDC, 2016).
Chronic Pain
The International Association for the Study of Pain (IASP) (2016) defines chronic
pain as pain which persists beyond three months (p. 11). Millions of United States
3

citizens, one-third of the population, in fact, are affected by chronic pain. Chronic pain
prevalence in the United States (US) is estimated to be greater than 30 million citizens.
Around 25 million of these individuals have moderate to severe pain. Chronic pain has
been shown to be greatly comorbid with other medical conditions (IASP, 2016).
The burden of dealing with chronic pain can diminish a patient’s psychological
well-being. The ability to maintain gainful employment, relationships with significant
others, and social activities may be limited; this can result in feelings of anxiety or
depression. Daily activity and quality of life are significantly lowered. Consequently,
Americans receive disability insurance primarily for pain. Stigma can also result from
patient encounters with healthcare providers who are not properly trained in the
management of chronic pain. Evidence reveals 40% to 70% of persons with chronic pain
are not receiving adequate medical treatment. Concerns for both over and under treating
in this population have been raised (IASP, 2016).
An estimated 5 to 8 million Americans use opioids for long-term management of
their chronic pain. Long-term, defined as greater than three months, opioid therapy for
chronic pain in adult patients is associated with increased risk of misuse and overdose.
Consequently, higher doses are associated with higher risks (Chou et al, 2015). While
some patients experience significant pain relief from opioids without adverse effects,
benefits and risks must be weighed. Many problems have been caused by the vast
number of opioids prescribed leading to their illicit use by the public (Reuben et al,
2015).
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Opioid Pain Medications
Prescription opioids are very potent pain medications and include oxycodone,
hydrocodone, and morphine among others (U.S. Food and Drug Administration, 2016).
Prescription opioid pain medications are used for severe pain, can have serious side
effects if not used correctly, and are often misused by patients. Patients may take higher
doses than prescribed to experience a state of euphoria and patients may also divert
medications to friends or relatives (McDonald & Carlson, 2013).
Opioid pain medications are scheduled drugs, or controlled substances, which are
regulated by the Food and Drug Administration. Scheduling classes are in place to
prevent misuse and abuse. Schedule I controlled substances are not used in medical
settings in the U.S. Schedule II has accepted medical use. Schedule II controlled
substances have a high potential for abuse and require a written and signed prescription
that may not be refilled. Examples of Schedule II opioid prescription medications are
fentanyl, hydrocodone, methadone, and oxycodone. Most commonly abused opioids are
hydrocodone and oxycodone (U.S. Food and Drug Administration [FDA], 2016).
Schedule III substances may lead to moderate physical dependence or high psychological
dependence. Buprenorphine is a Schedule III opioid substance used for medicationassisted treatment (MAT) of OUD. Schedules IV and V have the lowest abuse potential.
Next, there are two main categories of opioid pain medications—immediate
release (IR) and extended-release/long-acting (ER/LA). IR are the most often prescribed
type of opioid and is used for breakthrough pain. ER/LA are opioids used for prevention
of baseline pain by maintaining a constant level of drug for 8-72 hours. The FDA (2012)
approved a Risk Evaluation and Mitigation Strategy (REMS) for ER and LA opioid
5

medications. REMS is a strategy to allow patient access to ER/LA opioid pain
medications through safe prescribing and reduction and management of risks for adverse
patient outcomes. Inappropriate prescribing leads to risk for misuse and abuse and
potential serious adverse patient outcomes including addiction, unintentional overdose,
and death (FDA, 2012, 2016).
Table 1
Opioid Controlled Substance Schedules I-V
Schedule I
No accepted
medical use in
US

Schedule II
Codeine
Fentanyl
Hydrocodone
Meperidine
*Methadone
Morphine
Oxycodone

Schedule III
*Buprenorphine

Schedule IV
No opioids
identified in
this class

Schedule V
Codeine (not
more than
200mg/100 ml)
and opium
preparations
(not more than
100 mg/100
mg or ml)

Note: *Used in medication-assisted treatment (MAT) of Opioid Use Disorder (OUD)

Opioid Misuse, Abuse and Addiction
Misuse involves the use of prescription medication in a way which is against
directions (American College of Preventive Medicine, 2016). Misuse can be grouped
into several categories:
•

Not taking the medication as prescribed

•

Bingeing

•

Injecting, crushing, snorting

•

Diversion

•

Aggressive behavior
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The American College of Preventive Medicine (2016) states abuse is selfadministration to alter one’s state of consciousness or to “get high.” Moreover, addiction
is a primary, chronic, neurobiological disease, with genetic, psychological, and
environmental factors. Addiction is characterized by 4 C’s impaired control, compulsive
use, continued use despite harm and craving (American College of Preventive Medicine,
2016). Tolerance and withdrawal are signs of physical dependence. Tolerance is defined
as a reduction in effect requiring increased dosages to produce desired effect.
Withdrawal symptoms to assess for are rapid heartbeat, agitation, insomnia, diarrhea,
sweating, and runny nose (Paone, Dowell, & Heller, 2011).
Self-medication describes use of a drug without consulting a healthcare
professional to alleviate stressors or disorders such as depression and anxiety (Shapiro,
Coffa, & McCance-Katz, 2013). Non-medical use is intentional or unintentional use of
legitimately prescribed medication in an un-prescribed manner for its psychic effect.
Individuals also often share their unused opioid prescription pain medications, unaware
of the dangers of nonmedical prescription opioid use (NMPOU). NMPOU leads to abuse
and addiction characteristic of OUD (CMS, 2016).
Opioid Use Disorder (OUD)
The Diagnostic and Statistical Manual for Mental Disorders (DSM-5) states
substance use disorder is evident when the repetitive use of alcohol and/or drugs causes
debilitation and failure to carry out activities of daily living involving home, school, or
work. For opioid use disorder, specifically, 2 of 11 criteria must be met over a 12-month
period (APA, 2013). Criteria include:
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(1) individuals with OUD often take opioids in larger amounts or over longer periods of
time than prescribed;
(2) they may possess a strong desire or have failed efforts to control opioid use; activities
to obtain, use or recover from opioids is carried out;
(3) individuals experience craving or urge to use opioids;
(4) recurrent opioid use results in a failure to fulfill major role obligations;
(5) there is continued opioid use despite problems;
(6) important tasks are given up;
(7) physical hazards are posed due to use;
(8) individuals with OUD persistently use opioids even with knowledge of physical or
psychological complications caused by the substance;
(9) tolerance is reached; and
(10)

withdrawal symptoms manifest. (American Psychiatric Association, 2013).

OUD has had an impact on special populations—adolescents, women, and
individuals ages 16-45. Through research efforts, misuse of prescription drugs has been
shown to affect young adults most, especially age 18 to 45 (CDC, 2016). In 2014,
467,000 adolescents were current nonmedical users of opioid prescription pain
medications, with 168,000 having an addiction (CDC, 2016). Women are more like to
have chronic pain and may become more dependent on prescription opioids more quickly
than men leading to OUD. Between 1999 and 2010, 48,000 women died of prescription
pain reliever overdoses (CDC, 2016). Patients that request prescription opioid pain
medications from primary care providers must be evaluated for risk of opioid pain
medication misuse/abuse. Screening for risk of opioid pain medication misuse/abuse
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may alert providers of possible opioid use disorder and help stratify patients per risk
level.
Prescribing
Primary care providers (PCPs), including nurse practitioners (NPs), manage
chronic pain and prescribe opioid pain medications. Currently, 49 of 50 states allow NPs
to prescribe controlled substances, including opioid pain medication. Nurse practitioners
may be granted controlled substances prescriptive authority through the state board of
nursing. Prescribing habits correlate with misuse, and misuse leads to problematic
opioid-related behavior including opioid use disorder (OUD) and accidental overdose;
therefore, screening for risk for misuse, abuse, and OUD prior to prescribing opioid pain
medications is recommended (CMS, 2017a).
Screening
Mitigation strategies to prevent OUD involve screening and lack thereof results in
missed treatment opportunities (Bowman, Eiserman, Beletsky, Stancliff, & Bruce, 2013).
The Opioid Risk Tool (ORT) is a self-reported screening tool utilized with patients 16
years of age and older in primary care settings to assess risk for opioid abuse (National
Institute of Drug Abuse, 2015). Patients with high risk have increased likelihood of
opioid use disorder and may require referral for treatment.
Needs Assessment
State Level
The state of Mississippi is a leading prescriber of prescription opioid pain
medication, ranked 5th in prescribing opioids nationally. In 2012, an equivalent of 1.2
opioid prescriptions for each citizen were prescribed (Mississippi State Department of
9

Health, 2016). Hydrocodone is the most commonly prescribed opioid in Mississippi. In
July 2016, 145,846 prescriptions equal to 8,343,259 dosage units were written (MSDH,
2016). Mississippi has the 30th highest national unintentional drug overdose mortality
rate (Levi, Segal, & Miller, 2013).
All providers are required to use the Mississippi prescription drug monitoring
program (PMP) when prescribing controlled substances (Mississippi Board of Medical
Licensure [MBOML], 2013: Mississippi State Board of Nursing [MSBN], 2016) to
decrease the number of opioid pain medications prescribed and unintentional drug
overdose. The PMP tracks the number of drug units prescribed, the number of providers
prescribing controlled substances for a patient, and the pharmacies used by the patient to
fill prescriptions for controlled substances. In the state of Mississippi, NPs have
prescriptive authority after meeting all MSBN requirements and may prescribe any
schedule of controlled substance after completion of 720 hours of monitored practice and
registration with the U.S. Drug Enforcement Agency (DEA) (MSBN, 2016). The MSBN
monitors inappropriate opioid prescribing practices by APRN with CSPA.
Local Level
While working as a family nurse practitioner (FNP) in the internal medicine
department of a primary care clinic, several patients have presented with complaints of
chronic pain. These patients request prescriptions for opioid pain medications often
reporting allergies to or ineffectiveness of non-opioid pain medications. Similar
encounters have been verbalized by other providers including physicians and nurse
practitioners. Each provider expressed lack of discernment with this group of patients.
As a student in a Doctor of Nursing Practice (DNP) degree program, completion of a
10

DNP project is a requirement for the degree. In my role as a nurse practitioner provider at
the primary care clinic and project director for this DNP project, a needs assessment of
the recognized practice problem was conducted to determine the extent of the problem in
the clinical practice setting. A chart review was conducted in collaboration with
executive staff and members of the internet technology (IT) department in efforts to
gauge an estimate of patients currently being treated for pain-related diagnoses. A
retrospective review of the previous 30 calendar days revealed a total of 66 initial and
established patient encounters with a diagnosis of chronic pain and documentation of
prescribing an opioid pain medication. There were 32 (48%) males and 34 (52%)
females identified in the chart review and twenty-six (39%) patients were between the
ages of 16-45. The most common ICD 10 diagnoses were M54.5 (low back pain) and
M79.7 (fibromyalgia). Only 20 (30%) patients seen were prescribed an opioid. Seven
(11%) patients had a history of substance-related disorders with no documentation of a
risk assessment performed. The majority of the patients 45 (68%) were seen by NPs.
Misuse of prescribed opioid pain medication is a problem pertinent to primary
care. Misuse may be prevented through proper prescribing consistent with evidence-base
practice recommendations for conducting a comprehensive assessment that includes
screening for risk of opioid pain medication abuse/misuse (CMS, 2017a). This DNP
project explores the PICOT question: “In patients 18-45 years of age, who present to a
primary care clinic requesting a prescription for opioid pain medication, will screening by
nurse practitioners identify patients at risk for opioid abuse leading to appropriate
intervention or referral?”
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The DNP project will focus on nurse practitioner providers in a designated
federally qualified health center (FQHC) and patient-centered medical home (PCMH)
primary care clinic in southeastern Mississippi. A FQHC is an organization which
qualifies for enhanced reimbursement from Medicare and Medicaid (CMS, 2017b). A
PCMH is a model in which treatment is facilitated by primary care providers to
coordinate needed care (NCQI, 2017). This DNP project will ask the question; find the
evidence; appraise; act; evaluate and reflect (Schaffer, Sandau, & Diedrick, 2013) to
ensure mitigation of risks related to opioid abuse. Proposed mitigation strategies include
NPs implementing an opioid abuse/misuse risk assessment screening tool in practice and
providing evidence-based interventions and referrals to hopefully, prevent OUD.
Outcomes extend beyond improved patient outcomes but also hopefully, promote better
prescribing practices by NP providers, and decreased health care costs.
Relevant Review of the Literature
Databases accessed for this review of literature include CINAHL, MEDLINE,
PsycARTICLES, and evidence-based treatment guidelines. Key terms used in the review
of literature were chronic pain, evidence-based practice, risk mitigation strategies,
identification, opioid pain medication, opioid use disorder, abuse, misuse, prevention,
primary care, and screening. The proposed aim of this DNP project is to determine if
nurse practitioners in a primary care setting are implementing evidence-based practice
guidelines to mitigate risk of prescription opioid pain medication abuse among patients
who request a prescription for opioid pain medication.

12

Management Strategies
In March 2016, the Centers for Disease Control and Prevention released
guidelines to provide recommendations for providers who prescribe opioid pain
medications. The guidelines are not intended for chronic pain related to active cancer
treatment, palliative care, and end of life care. Initiation, selection, dosage, duration,
follow-up, discontinuation, assessing risk and addressing harms of opioid use are
addressed through twelve recommendations.
•

Non-pharmacologic treatment is preferred. If pharmacologic treatment is
warranted, non-opioid treatment should be initiated with or without opioid
pharmacologic therapy as appropriate.

•

Providers should establish treatment goals with each patient prior to initiation
of treatment. Goals for pain and function should be realistic. If there is
clinically significant improvement in pain and function which outweighs risks
to patient safety, opioids may be continued.

•

Known risks should be discussed with all patients prior to starting therapy as
well as periodically. Patient and provider responsibilities should be outlined
(CDC, 2016).

•

Immediate-release opioids should be prescribed when starting therapy instead
of extending release/long-acting opioids.

•

Lowest effective dose should be prescribed at start.

•

No greater quantity than necessary for the anticipated duration of severe pain
should be prescribed. Three days or less will often suffice. Rarely, greater
than seven days is needed for acute pain (CDC, 2016).
13

•

Benefits and harms should be evaluated within the first four weeks especially
before dose escalation. The goal is to taper opioids to lower doses or
discontinue all together is deemed safe.

•

Consideration of offering naloxone is indicated for patients with increased risk
of overdose such as a history of substance use disorder; higher opioid dosages;
concurrent benzodiazepine use; or history of overdose.

•

Providers should review patients’ Prescription Monitoring Program (PMP)
when starting opioid pain medications and periodically during treatment for
chronic pain (CDC, 2016).

•

Use of urine drug testing is also recommended when starting opioid pain
medications as well as periodically during treatment, at least annually.

•

Clinicians should avoid prescribing opioid pain medication to patients
currently taking benzodiazepines.

•

Providers should offer or arrange evidence-based treatment for patients with
opioid use disorder (CDC, 2016).

The American Pain Society (APS) and the American Academy of Pain Medicine
(AAPM) comprised a panel to develop an evidence-based guideline on chronic opioid
therapy (COT) for individuals with chronic pain (Chou et al., 2009). The investigators
reviewed 8,034 abstracts. A total of 14 systematic reviews and 57 primary studies were
included in the report of evidence. The expert panel recommends clinicians first obtain
appropriate diagnostic tests for evaluation of any underlying conditions. Consideration of
the effectiveness of non-opioid therapy should precede COT. Reliable evidence on
14

methods to assess potential benefits of COT is limited. Screening tools for the
assessment of potential risks of COT are helpful for risk stratification. More validation
studies are needed however to explore outcomes. The ORT has been shown to have
construct partial validity. The strongest factor predictive of drug misuse after initiation of
COT is a personal or family history of alcohol or drug abuse. Patients should receive
informed consent and participate in their opioid manage plans. Initiation and titration of
COT follow. An initial trial typically lasts from several weeks to several months.
Proceeding beyond this time frame warrants careful consideration of trial outcomes.
Clinicians should monitor and reassess patients on COT periodically. Urine drug screens,
as well as other information to determine adherence, are useful, but quality of evidence
regarding these measures is low as well. When pain is accompanied by comorbidities,
clinicians should integrate or refer for therapies that target psychosocial factors.
Cognitive-behavioral therapy is consistently shown to be effective for chronic pain.
Functional restoration and specific behavioral interventions in addition to pain education
have been shown to improve strength. Interdisciplinary or multidisciplinary pain
management and rehabilitation approaches are recommended for high-intensity chronic
pain patients at high risk for opioid use disorder to coordinate physical, vocational, and or
psychological components of care (Chou et al, 2009).
Prevention, assessment, and treatment of chronic pain is challenging. Insufficient
evidence exists that pain relief is sustained or function is improved when opioids are
prescribed for chronic pain (Paone et al., 2011). To prevent misuse providers should
avoid prescribing opioids for chronic pain unless other pharmacological and or nonpharmacological approaches have been ineffective. Also, whenever possible, opioids
15

should not be prescribed in patients taking benzodiazepines because of the risk of fatal
respiratory depression (Paone et al., 2011). Chronic opioid therapy (COT) to treat pain,
aside from severe acute pain or chronic malignant pain, remains a topic of controversy.
Selection of patients for an opioid trial should follow weighing of potential benefits and
risks of COT (Paone et al., 2011).
Management of Pain by Healthcare Professionals
Pain is one of the most common reasons for health care visits; however, most
health professionals’ educational programs do not adequately prepare them to effectively
manage pain. Core competencies such as basic knowledge, assessment, team-based care
and cultural competency are integral. The National Pain Strategy recommends
strengthening evidence base for pain prevention strategies, assessment tools, and outcome
measures. Rigorously researched efforts are warranted. This is particularly relevant to
primary care. Improvements in self-management strategies in patients with chronic pain
are also necessary. Treatment should start with a comprehensive approach. Plan of care
should address biological, psychological and social aspects (The Interagency Pain
Research Coordinating Committee, 2015).
Researchers note no single practice change in prescribing behavior alleviates all
risks. Still, regular monitoring and reassessment provide opportunities to minimize the
risks associated with long-term opioid use by allowing for the tapering and discontinuing
of opioids among patients who are not receiving a clear benefit or among those who are
engaging in practice that increase the risk of overdose (Volkow & McLellan, 2016).
Examples of such practice are consumption of high doses of alcohol, concurrent use of
benzodiazepines, and poor adherence to opioid medication regimen. Prevention of drug
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diversion, reduction of risk of overdose, and minimization of the risk of addiction are
presented as goals. Recommendations to achieve this involves increased use of evidencebased prescribing and management practices. The extended prescription of opioids for
the treatment of chronic pain has questionable benefits, and the risks of overdose
increases with higher doses. There is also a call for increased research on pain.
Discovery-oriented research has been recommended to identify potent non-opioid
analgesics and other pain treatment strategies (Volkow & McLellan, 2016).
Screening for Opioid Misuse/Abuse Risk
Clinicians need to identify patients at risk of misusing prescribed opioids in order
to safely monitor therapy. Opioid misuse carries the risk of development of addiction,
overdose, and death (Claxton & Arnold, 2011). Providers must balance each patient’s
pain and risk levels. Patients with higher risk should be monitored more intensely than
patients with lower risk. Risk factors for misuse may be grouped into three categories (1)
biological, (2) social, and (3) psychological. Biological risk factors are family history of
drug abuse and male gender. Poor social support and history of drug-related criminal
chargers are social risk factors. Finally, psychological risk factors include personal
history of substance abuse, preadolescent history of sexual abuse, and comorbid
psychiatric illness. Personal history of substance abuse includes alcohol or tobacco.
Examples of comorbid psychiatric illnesses are major depression, bipolar disorder, and
personality disorder (Claxton & Arnold, 2011).
Screening Tools for Opioid Misuse/abuse
Common screening tools for opioid misuse in patients with chronic pain are
Screener and Opioid Assessment for Pain Patients (SOAPP) and the Opioid Risk Tool
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(ORT). However, these tools have not been fully validated. The SOAPP predicts risk for
possible aberrant drug behavior using a 14 item self-report. Responses are based on a 5point Likert scale. With 7 as a cutoff score, the test has sensitivity of 91%, specificity of
69%, positive predictive value (PPV) of 71%, negative predictive value (NPV) of 90%
(Claxton & Arnold, 2011). The ORT is a 5 item yes or no tool which predicts the
probability of opioid misuse or abuse among patients being considered for opioid therapy
for chronic pain. Patients are categorized as low, medium, and high risk. Sensitivity and
specificity for patients who score at least medium risk are 99% and 16% respectively.
The tool is best applied in primary care settings. Clinicians must be aware these
screening tools have been used in studies to identify high-risk patients. The tools are not
diagnostic of substance use disorders or to accurately identify patients who should not be
prescribed opioids for chronic pain (NIDA, 2015). Furthermore, they do not assess the
risk of diversion of drugs. Regardless of if a provider chooses to use a tool, a thorough
history is crucial to identify patients who require closer assessment, monitoring and or
referral (Claxton & Arnold, 2011).
Evidence supporting risk assessment tools for identification and prevention of
opioid use disorder is inconsistent. Standardized tools lack sufficient sensitivity and
specificity (Shapiro et al., 2013). Still, screening is paramount assuming all patients are
at risk. Fundamental comprehensive clinical assessment is necessary for all patients
taking opioids for management of chronic pain. Evaluation should include (1) pain
intensity appraisal; (2) functional status; (3) quality of life and (4) known risk factors for
potential harm. Known risk factors are (a) medical comorbidity, (b) history of substance
use disorders or current substance use, (c) mood disorders and (d) concurrent use of
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medications with potential drug-drug interactions. Patients at highest risk for harm
should have more structured monitoring during follow-up visits at regular intervals
(Reuben et al., 2015). A comprehensive assessment, evaluation of risk, screening, brief
intervention and referral to treatment are indicated in the clinical setting when managing
patients presenting with complaint of chronic pain.
Screening, Brief Intervention, and Referral to Treatment (SBIRT)
The SBIRT model was developed following an Institute of Medicine
recommendation which solicited community-based screening for health risk behaviors.
SBIRT consists of three major components. The first component is screening.
Screening
A healthcare professional assesses a patient for risky substance use behaviors
using standardized screening tools. Screening provides a quick method of identifying
patients who use substances at at-risk levels in addition to those who may already
experience substance use-related issues. A brief one to three question prescreen is
administered. If an individual screen is positive, a longer screening is given. Screening
can occur in any healthcare setting (Substance Abuse and Mental Health Services
Administration [SAMHSA], 2016).
Suggested screening tools are the drug abuse screening test (DAST), a sensitive
screening tool for drug abuse. The ORT has been validated and fits recommendations for
a longer screening tool. Utilizing the SBIRT model in a study of more than 499, 000
patients using the DAST, 22.7% of patients were identified as high-risk users or had a
current substance use disorder. There was a 67.7% decline in reported illicit drug use at
follow-up (McCance-Katz & Satterfield, 2012). Those who received specialty
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experienced great improvements in general and mental health; employment; housing
status; and criminal behavior.
Opportunities for early intervention involving at-risk substance users include
primary care centers, emergency rooms, trauma centers, and other community health
settings. Screening assesses severity of and identifies the appropriate level of treatment.
The Center for Substance Abuse Treatment/Substance Abuse and Mental Health Services
Administration has launched a training program to foster SBIRT clinical skills in support
of innovations and implementation of SBIRT. In addition, reimbursement billing codes
exist for providers that implement SBIRT. Current procedural terminology or CPT codes
used are: CPT 99408 for alcohol and or substance abuse structured screening from 15-30
minutes and CPT 99409 for alcohol and substance abuse structured screening exceeding
30 minutes commercial insurance billing purposes; G0396 and G0397 codes may be used
for Medicare for alcohol and/or substance use (not tobacco) structured assessment and
brief intervention 15-30 minutes and greater than 30 minutes, respectively; and H0049
and H0050 may be used to bill for Medicaid alcohol and/or drug screening (McCanceKatz, & Satterfield, 2012; SAMHSA, 2016).
Brief Interventions
Brief interventions are evidence-based practice designs aiming to motivate
individuals at risk of substance abuse to make behavior changes. A healthcare
professional engages a patient in a short conversation, providing feedback and advice.
Brief intervention can also be used for at-risk patients to become more receptive to utilize
referral services. In primary care settings, brief interventions consist of 5 minutes of brief
advice. The interventions are ideal to treat problematic or risky substance use—not
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intended to treat individuals with serious substance dependence. Cognitive behavioral
therapy and motivational interviewing, or a combination of the two, are the two most
common behavioral therapies used in SBIRT programs (SAMSHA, 2016). Brief
intervention without cognitive behavioral therapy will be used for this project.
FLO and BNI are acronyms for two common forms of motivational interviewing.
Each will be discussed in this section. Brief Negotiated Interview and Active Referral to
Treatment (BNI-ART): Provider Training Algorithm (Appendix A) is a flowchart
created by the Boston University School of Public Health which includes brief screening
questions health practitioners can ask during brief intervention. Steps includes a listing of
questions and responses that a health provider can use during a brief intervention. With
BNI, providers raise the subject, provide feedback, enhance motivation, and negotiate
and advise. The tool focuses on; building rapport initially; then raising the subject and
discussing daily life; discussing pros and cons of use; asking permission; giving
information, and eliciting reaction; discussing readiness to change, and reinforcing
positives; creating an action plan; and identifying strengths. The final stage is
prescription for change which involves writing down an action plan and sealing the deal.
Patients are provided handouts and follow-up to discuss progress is suggested
(SAMSHA, 2016).
The FLO Model includes providing F-feedback, L-listening and understanding,
and exploring O-options. FLO is often reinforced with S.E.W. S-summarize patient’s
statements in favor of change. E-emphasize their strengths. W-what agreement was
reached? (SAMSHA, 2016).
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Referral for Treatment
Referral is provided for patients who screen high risk and need additional
services. Referral to treatment is critical yet often underutilized (SAMSHA, 2016). The
process consists of assisting with accessing specialized treatment. Community Care of
North Carolina (CCNC) has developed a set of three referral forms in partnership with
other stakeholders to orchestrate easier consultation and follow-up. These are Bridging
the Gap Between Primary Care and Behavioral Health-Referral Forms (SAMSHA, 2016).
An in-house referral form will be used for this project.
In summary, the review of literature shows that implementing SBIRT (SAMSHA,
2016) and other evidence-based practice recommendations (CDC, 2016) are effective in
minimizing the risk for misuse of opioid pain medication. Opioid therapy for chronic
pain is associated with increased risk of misuse and overdose as well as other physical
conditions (CDC, 2016). Experts suggest inappropriate prescribing contributes to misuse
of prescription opioid pain medication (Shapiro et al., 2013). The American Pain Society
(APS) (2016) states a reliable instrument for identifying aberrant drug-related behaviors
could be valuable for ongoing monitoring of risks and benefits of chronic opioid therapy.
ORT should be used with other combined strategies. The APS and American Academy
of Pain Medicine (AAPM) (2016) recommend coordination of care when the services of
other health care professionals are needed. Coordination of care also minimizes misuse
of opioid pain medications. Prescribers should make referrals as needed. The American
Society of Addiction Medicine (ASAM, 2016) recommends a combination of
psychosocial interventions and medications for the treatment of opioid use disorder. A
table summarizing the ROL can be found in Appendix B.
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Using the Iowa Model of evidence-based practice (Titler et al., 2001), this DNP
project will ask the question; find the evidence; appraise; act; evaluate and reflect to
ensure mitigation of risks related to opioid misuse (Schaffer, Sandau, & Diedrick, 2013).
This DNP project will ask the question are providers utilizing evidence-based guidelines
which include implementation of SBIRT prior to prescribing opioid pain medication.
Finding and appraising of the evidence was carried out through relevant review of
literature. Acting will require education of the providers on prescription opioid drug
misuse and the importance of utilizing evidence-based guidelines in practice. In addition,
SBIRT will be implemented over a 4-6-week period with all initial encounters involving
patients requesting a prescription for an opioid pain medication. Evaluation and
reflection is necessary to ensure mitigation of risks related to opioid misuse (Schaffer et
al., 2013). Specifically, the project will evaluate whether implementing SBIRT in
conjunction with evidence-based guidelines by nurse practitioner providers mitigates the
risk for prescription opioid pain medication misuse and abuse among patients requesting
a prescription for opioids in a primary care setting.
Conceptual Framework
The conceptual framework used for this project is the SBIRT Program Matrix.
This framework is used for program implementation and evaluation. SBIRT Program
Matrix has five components: (1) SBIRT services; (2) performance sites; (3) provider
attributes; (4) patient/client populations; and management structure and activities.
Implementation outcomes include but are not limited to program adoption, fidelity, costs,
and grant compliance (Del Boca, McRee, Vendetti, & Damon, 2017). SBIRT services
includes risk factors, instruments, approaches, procedures. Examples are pre-screening,
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screening, brief intervention, referral to treatment, brief treatment, and added services.
Participating providers will offer SBIRT services using the five components of this model
at a rural health primary care clinical site. Screening with the ORT for those with a
positive preliminary screen will be carried out. Brief intervention and referral to
treatment will be implemented for high-risk patients. The performance site is a federally
qualified health center and patient-centered medical home. The NP provider attributes
include management of patient population through knowledge and structured skills
obtained from appropriate educational tools and resources. Additional provider attributes
include personal characteristics, clinical training, educational attainment, self-efficacy,
treatment philosophy, and counseling experience. For this project, patient/client
population presenting requesting an opioid prescription will be assessed for risk status,
demographic characteristics, and physical and mental health. Management structures and
activities include evidence-based protocols; coaching and staff evaluation; program
evaluation and dissemination; as well as facilitative administrative supports, systems
interventions and sustainability planning are all necessary components of SBIRT program
implementation and evaluation (Del Boca et al., 2017).
DNP Essentials
The project aims to implement a change in prescribing practices of NP primary
care providers at a primary care health center in efforts to mitigate the risk of misuse of
prescription opioid pain medications in patients requesting a prescription for opioid pain
medication. DNP essentials and competencies (American Associations of Colleges of
Nursing, 2014) are fulfilled upon completion of this DNP project (Appendix C).
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Evaluation Plan
The logic model (Appendix D) demonstrates how the project director will
evaluate outcomes. The project director used the SBIRT tool to provide training to
stakeholders. Stakeholders in this study are identified as nurse practitioner providers who
treat patients that present requesting prescriptions for opioids with the potential for opioid
misuse if opioid pain medication is prescribed. The project director (PD) trained the
providers and administrators on the risk as well as appropriate use of the SBIRT
algorithm with incorporation of ORT. The providers then implemented the use of the
tool in the clinical setting. The PD will evaluate adherence to the training and fidelity to
use of the instrument by analyzing administration of the tool in the clinical setting, use of
intervention after assessing risk, and whether an opioid was prescribed. The analysis will
reach the medium-term goals with the idea that the accurate implementation of the tool
and following risk assessment protocols could potentially lead to a reduction in opioid
misuse and abuse.
Assumptions
The assumption is once educated providers change their prescribing habit and
adopt evidence-based practice recommendations, the risk of patients misusing
prescription opioid pain medications will be lowered. Patients will have improved
overall health outcomes, and costs will be lowered for insurers and consumers alike.
Purpose of the DNP Project
The purpose of the DNP project is to determine if nurse practitioner providers are
implementing evidence-based practice guidelines including Screening, Brief Intervention,
and Referral to Treatment (SBIRT) (McCance-Katz & Satterfield, 2012) to mitigate risk
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of prescription opioid pain medication misuse and abuse among patients who request a
prescription for opioid pain medication.
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CHAPTER II - METHODS
The purpose of this DNP project was to determine if nurse practitioners (NPs) in a
primary care setting were utilizing screening, brief intervention, and referral for treatment
(SBIRT), prior to prescribing opioid pain medications for patients seen on an initial visit
requesting a prescription for opioid pain medication. The desired outcome was to
mitigate the risk for opioid pain medication misuse or abuse while providing appropriate
chronic pain management.
Setting
The setting was a patient-centered medical home (PCMH), designated as a
federally qualified health center (FQHC) located in rural Mississippi. The clinic serves
pediatric to geriatric patients. Most of the patient population receives Medicare and/or
Medicaid benefits; a sliding scale fee is offered to eligible patients who are uninsured,
and private insurance is also accepted at the facility. Services offered include internal
medicine; pediatrics; women’s health; women, infants and children (WIC); dental; vision;
pharmacy; and social services.
There are four clinic locations: Site 1 (main clinic), Site 2, Site 3, and Site 4
(satellite clinics). There are five NPs on staff at the main clinic—3 full-time, 1 part-time,
and 1 that works as needed (prn). Both Sites 2 and 3 are staffed by 1 full-time NP each
but were excluded from the project. Site 4 is only staffed by medical doctors and was
excluded from the project. The DNP project was only conducted with the five full-time
nurse practitioners that see patients age 18 to 45 years of age at the main clinic-Site 1.
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Population
Participants included nationally certified adult-gerontological and family nurse
practitioners, AGNPs (N=2) and FNPs (N=3). The full-time NPs are licensed to practice
in the state of Mississippi and work at the primary care main clinic setting. All five of
the participants completed 720 hours of monitored practice as required by the Mississippi
Board of Nursing (MSBN, 2016) deeming them eligible for controlled substance
prescriptive authority (CSPA). The majority of patients between the ages of 18-45 years
of age with a diagnosis of chronic pain are seen by nurse practitioners; therefore, nurse
practitioner prescribers were the targeted populations for the DNP project.
Design
The design was descriptive in nature. The protocol describes the implementation
of SBIRT in patients requesting a prescription for an opioid pain medication seen by NPs
in a primary care setting. The primary project outcome was identification of risk for
opioid misuse or abuse in patients, while secondary or long-term outcomes include
reduction in misuse of opioids, better prescribing practices, healthcare cost reductions,
and improvement in public health and safety.
Procedures
Education Session
The project director is a full-time FNP employee, with CSPA, at a primary care
clinic in southeastern Mississippi. In a one-on-one educational session, NP providers
were educated by the project director on current evidence-based opioid guidelines to
include conducting a comprehensive assessment and screening for opioid misuse/abuse,
brief intervention, and referral for treatment (SBIRT) (CDC, 2016; SAMHSA, 2016).
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The educational session covered the most common pain diagnoses seen in the
clinic; conducting a comprehensive assessment, and implementation of SBIRT. The
project director defined chronic pain and all applicable ICD-10 diagnosis codes,
excluding active cancer; palliative; or end-of-life-care. Participants were educated on
how to conduct a comprehensive assessment based on evidence-based guidelines (CDC,
2016) and implement Screening, Brief Intervention, and Referral for Treatment (SBIRT)
(SAMSHA, 2016). NP participants were also instructed to use the prescription
monitoring program (PMP). Education was provided on known risk factors such as
illegal drug use; prescription drug use for nonmedical reasons; history of substance use
disorder or overdose; and mental health conditions.
Screening in SBIRT was modified to use a screening tool that identifies risk for
opioid use or misuse rather than the longer screening for substance use-DAST. The
participants were also educated regarding use of the Opioid Risk Tool (ORT) developed
by Lynn R. Webster, MD (Appendix E). The tool is a self-report screening tool to assess
risk for opioid abuse or misuse in individuals, age 16 to 45 (National Institute on Drug
Abuse [NIDA], 2015). The ORT addresses family as well as personal history of
substance abuse—alcohol, illegal and prescription drugs. History of preadolescent sexual
abuse and questions regarding psychological disease are included. Providers were
advised to read the tool to the patient when administering the tool and assigning points
based on patient’s responses. Points were assigned based on male or female sex. Points
were then summed up by providers to note mild, moderate, or high risk. The ORT has
been validated in both males and females with a diagnosis of chronic pain. In a
preliminary study, a high degree of sensitivity and specificity was shown using a c
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statistic for validation. Excellent discrimination was displayed, c=0.82 male and c=0.85
female. Patients categorized as high-risk are at increased likelihood of developing opioid
use disorder (OUD) (NIDA, 2015).
Providers were informed on brief interventions to implement and referral for
treatment based on scoring of the ORT. Brief interventions should be utilized for patients
identified as mild to moderate risk prior to prescribing opioid pain medication. Providers
were instructed on using a brief negotiated interview (BNI), motivational interviewing for
a period of 5 minutes (SAMSHA, 2016). Patients identified as high risk were referred for
behavioral health/addiction services in addition to brief intervention. A list of referral
sites in the surrounding area was provided for providers.
Consent
After the educational session, providers were asked to participate in the proposed
project. Providers were informed of the project and informed consent for participation
was obtained from all providers willing to participate in the project. All practitioners
were made aware of the option to opt out of the project. For those participants willing to
participate in the project after being invited and having received the informed consent
statement, data collection tools were provided. An overview of completing the data
collection tools after implementing SBIRT was provided for participating providers.
SBIRT Implementation
Participants were instructed on implementing SBIRT in patients that presented
for an initial visit requesting a prescription for an opioid pain medication over a 4 to 6week interval in a primary care clinic in rural southeastern Mississippi. Participants
implemented SBIRT on all new patients meeting criteria, age 18-45 and requesting a
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prescription for an opioid pain medication. Based on the review of literature (NIDA,
2015) which noted young adults age 18-45 at highest risk for misuse, patients less than 18
years of age or older than 45 years of age were excluded. Pregnant patients are also
excluded due to vulnerability
Before prescribing opioid pain medications, providers were informed to conduct a
comprehensive assessment based on evidence-based guidelines (CDC, 2016) on any
individuals meeting inclusion criteria during an initial visit requesting pharmacological
treatment with an opioid pain medication. Prescreen data was collected by participating
NP providers to identify patients’ risk for OUD. A comprehensive assessment included a
risk assessment and interventions, including referral for treatment for opioid use disorder,
and was provided based on the results or the risk assessment (SAMSHA, 2016)
(Appendix F). Patients were first asked about past drug use to determine whether
additional screening was necessary: In the past year, how many times have you used
illegal drugs and/or prescription drugs for nonmedical reasons (prescreen)? If the risk
screen was negative, participants followed evidence-based guidelines (CDC, 2016) but
did not report on negative screens. If the preliminary screening was positive, risk level
was determined further through the Opioid Risk Tool (ORT) which was provider
administered. Participants provided brief intervention as needed. Brief intervention
consisted of 5 minutes of motivational interviewing to assess readiness for positive
behavioral change. All patients received screening and/or brief intervention depending
on risk level. Brief intervention was utilized for patients identified as mild, moderate, or
high risk prior to prescribing opioid pain medication. This project focused on
motivational interviewing (BNI) for a period of 5 minutes (SAMSHA, 2016). Patients
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identified at mild or moderate risk were treated according to the CDC (2016) guidelines
for prescribing opioids for chronic pain. Only patients at high risk received referral for
treatment. Patients at high risk were referred to local behavioral health/addiction
services.
Data Collection
A data collection tool, the ORT, BNI, and list of referral sources was provided to
participants. Participants administered and documented results of the ORT and BNI
during patient visits. Data was documented on a data collection tool by NP providers.
Patients were categorized on the data collection tool by age group; sex; level of risk for
opioid abuse (low: 0-3, moderate: 4-7, or high >8); and brief intervention treatment (yes
or no) with prescription for opioid treatment (yes or no); or referral for treatment (yes or
no).
Ethical Protection of Human Subjects
There were minimal risks of harm to participants associated with this project. The
project consisted primarily of participants, nurse practitioners (NP) providers,
documenting screening, brief intervention, referral for treatment on a data collection tool.
Data documented was reported in the aggregate, no single person was identified.
Data was anonymous via de-identification and was protected using coding, and cannot be
associated with individual subjects; therefore, loss of privacy and breach of
confidentiality was not a risk. Although the project director knows who the providers
\were, the association of providers to which data was accessible, only by listing the first
initial of the provider's last name. The project director will made weekly follow-ups to
answer any questions and ensure fidelity of procedure.
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The project consisted of data with no identifying information. Data was recorded
on the ORT and other data collection tools by the trained data collectors so that subjects
could not be identified, directly, or through identifiers linked to the subjects. To ensure
confidentiality and anonymity, subjects’ information was stored using codes assigned on
the data collection form. Data on the data collection tool was stored under double locks
in the office files of the data collector at the clinic. The data collector was the only person
who had access to the double locked office file. The data collection tools were placed in
an envelope by the data collector to be given to the project director (PD) on a weekly
basis for analysis and completion of the project. The project director provided any
assistance necessary to ensure efficiency of data collection.
Information on the data collection tool was entered in an Excel spreadsheet by the
project director to maintain confidentiality. Data was recorded and summarized by the
Project Director so that subjects could not be identified, directly, or through identifiers
linked to the subjects. Electronic data wad stored on a password protected computer.
Confidentiality was protected by placing all physical data collected in a locked file box
that was kept in the office of the PD and only the PD had access to the locked file box
and drawer. All collected data forms will be destroyed by shredding after completion of
the project 6 months post-graduation from the DNP degree program.
Participation in the DNP project was completely voluntary without risks or
incentives and any participant had the option to decline participation at any time without
penalty. Providers who agreed to participate may have feared occupational consequences
if they did not participate, but were assured of no consequences for nonparticipation on
the consent given prior to participation. Other inconveniences that the NP participants
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may have experienced were time constraints in implementing a component of an
evidence-based guideline into daily practice.
Potential benefits participants may have gain as a result of participation in the
project were improved evidence-based prescribing practice to minimize the risk for
opioid pain medication misuse/abuse among patients seen by NPs in a primary care
setting. In addition to identification of risk for opioid misuse or abuse and reduction in
misuse of opioids, additional benefits included healthcare cost reductions and
improvement in public health and safety.
Data Analysis
The project director evaluated use of evidence-based practice recommendations
for SBIRT to include outcome categories of risk assessment screening for opioid
abuse/misuse; brief intervention and referral. Data was retrieved through data collection
tools provided to providers to answer the PICOTs question: “In patients 18-45 years of
age, who present to a primary care clinic requesting a prescription for opioid pain
medication, will screening by nurse practitioners identify patients at risk for opioid abuse
leading to appropriate intervention or referral?” Data was stratified based on age (18-25),
(26-35), (36-45); sex (male or female), risk level (low, moderate, high), opioid therapy
initiated (yes or no), brief intervention (yes or no) and referral (yes or no). Patient
follow-up information was not included in this project. Data was analyzed using
descriptive statistics.
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CHAPTER III - RESULTS
The purpose of this DNP project was to determine if nurse practitioners in a
primary care setting are implementing evidence-based practice guidelines (CDC, 2016) to
mitigate risk of prescription opioid pain medication abuse among patients who request a
prescription for opioid pain medication. During the 4 week period of data collection,
beginning February 1st and ending March 1st, 12 patients were identified that met criteria
for inclusion in the study. Two NP providers participated in data collection for the study
and saw 100% of the patients.
The ORT revealed 42% (5) of patients had a family history of alcohol abuse; 17%
(2) patients had a family history of illegal drug abuse, and 0.08 % (1) patient had a
personal history of illegal drug abuse. 25% (3) of patients had a history of preadolescent
sexual abuse, while17% (2) of patients had a history of attention deficit disorder (ADD),
obsessive compulsive disorder (OCD), bipolar, and/or schizophrenia and 42% (5) of
patients had a history of depression. There were several identified risk factors for which
none of the patients reported having, such as, family history of prescription drug abuse,
and personal history of alcohol abuse. All descriptive data are represented in Table 2.
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Table 2
Descriptive Statistics
Std.
N Minimum Maximum Mean Deviation
age
sex
Risk level
intervention
referred
Opioid prescribed
FH alcohol
FH illegal drugs
FH Rx drugs
PH alcohol
PH drugs
PH Rx drugs
age1645
PA Sex Abuse
ADD_OCD_ETC
depression
Score totals
Valid N (listwise)

12
12
12
12
12
12
5
2
0
0
1
0
12
3
2
5
12
0

1
1
1
1
1
2
1
3

3
2
3
2
2
2
3
3

1.50
1.50
1.50
1.83
1.83
2.00
1.80
3.00

.905
.522
.798
.389
.389
.000
1.095
.000

4

4

4.00

.

1
0
2
1
1

1
3
2
1
9

1.00
1.00
2.00
1.00
3.58

.000
1.732
.000
.000
2.999

The largest portion of the sample based on age group was age 18-25 comprising
75% (9) of the total sample size. The remainder of the study sample was composed of
36-45 year old making up 25% (3). No patients in the sample fell into the 26-35 age
range. The sample was split evenly between males and females. 66% (8) of patients
were identified as low risk scoring 0-3--everyone scored at least 1 due to age criteria of
16-45 for use of the ORT. The average score for the low-risk category was two). 17%
(2) of patients were identified as moderate risk scoring between 4 and 7.

Lastly, 17%

(2) of patients were identified as high risk. These data are represented in Table 2 below.
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Table 3
Risk Level
Valid Cumulative
Frequency Percent Percent Percent
Valid low

8

66.0

66.0

66.0

moderate

2

17.0

17.0

83.0

high

2

17.0

17.0

100.0

Total

12

100.0

100.0

Brief intervention was not performed for any of the low to moderate risk patients.
Brief intervention and referral for treatment was performed in high-risk patients as
indicated in Table 3.
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Table 4
Risk Level Intervention Cross Tabulation
intervention
yes
Risk level

Total

no

Total

low

0

8

8

moderate

0

2

2

high

2

0

2

2

10

12
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CHAPTER IV – DISCUSSION
This DNP project was designed to implement a change in prescribing practices of
nurse practitioner (NP) healthcare providers at a primary care health clinic in efforts to
mitigate the risk of misuse of prescription opioid pain medications in patients requesting
a prescription for opioid pain medication. Misuse of prescribed opioid pain medication
is a problem pertinent to primary care and may be prevented through proper prescribing
consistent with evidence-based practice recommendations. NP practitioner providers
were educated on conducting a comprehensive assessment that includes screening for risk
of opioid pain medication abuse/misuse (CMS, 2017a). Education was also provided on
known risk factors for opioid misuse and abuse such as illegal drug use; prescription drug
use for nonmedical reasons; history of substance use disorder or overdose; and mental
health conditions. Risk level for misuse and abuse of opioid pain medication was
identified through screening using the Opioid Risk Tool (ORT) for those patients with a
positive preliminary screen. Brief intervention and referral to treatment was conducted
for patients identified as high risk for opioid misuse.
Screening, Brief Intervention, and Referral for Treatment (SBIRT)
The SBIRT model was developed to screen for health risk behaviors in
community-based settings. Risk factors for opioid misuse may be grouped into three
categories (a) biological, (b) social, and (c) psychological (Claxton & Arnold, 2011). A
priority area within the CMS (2017a) person-centered strategies to decrease opioid
misuse is to expand screening, diagnosis, and treatment of opioid use disorder. Screening
was conducted to identify risk for opioid misuse/abuse and interventions were provided
to prevent opioid use disorder. Biological and psychological factors that predict OUD
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were considered when NP participants administered the Opioid Risk Tool (ORT) to those
patients with a positive preliminary screen. Opioid use disorder (OUD) has been found in
patients with comorbid mental disorders and physical conditions; therefore, assessing the
psychosocial components of the ORT and conducting a comprehensive assessment are
essential in primary care settings (Katz et al., 2013).
Another priority in the CMS (2017a) opioid misuse strategy is prescribers are to
increase the use of evidence-based practices for acute and chronic pain management.
After screening for opioid misuse/abuse risk, treatment should start with a comprehensive
approach. The plan of care should address biological, psychological and social aspects
(Interagency Pain Research Coordinating Committee, 2015). When pain is accompanied
by comorbidities, clinicians should integrate or refer for therapies that target psychosocial
factors. Two (17%) of patients received brief intervention, motivational interviewing, and
were referred for treatment. Pain management and rehabilitation approaches are
recommended for patients with chronic pain that are identified as high risk for opioid use
disorder to coordinate physical, vocational, and or psychological components of care
(Chou et al., 2009).
Prescribing Practices
Safe prescribing models for chronic pain management have been developed for
prescribing opioids. (CDC, 2016). The NP participants exercised healthy prescribing
habits as evidenced by not prescribing any opioid therapy in the 12 patients that presented
requesting a prescription for an opioid pain medication. Prescribing practices are directly
correlated with patient risk--healthy prescribing habits leading to lower risk and
unhealthy prescribing habits are associated with higher risk (CDC, 2016). Data reveals
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implementation of evidence-based guidelines since most patients were low risk, and no
opioids were prescribed. Implementation of best practice was desired due to
recommendations against initiating pharmacological therapy with opioids unless other
pharmacological and nonpharmacological therapies have been ineffective previously
(CDC, 2016; Paone et al., 2011). The assumption is once educated providers change their
prescribing habit and adopt evidence-based practice recommendations, the risk of
patients misusing prescription opioid pain medications will be lowered.
Limitations
Only two NP participants implemented SBIRT in 12 patients during the short
period for the project. While five NP providers were educated on evidence-based
guidelines for prescribing opioid pain medication and SBIRT, patients that met the
inclusion criteria for age 18-45 did not present to one provider requesting a prescription
for opioid pain medication. The patient population seen by the NP were primarily adults
over the age of 45. Two providers were on medical leave for most of the data collection
period. Another limitation of the project is that patients may not have been completely
honest in responses to the questions on the ORT due to stigma associated with substance
misuse and other components of the ORT. For example, all patients denied a family and
personal history of prescription drug abuse.
Implications
Practice Implications
While conducting a needs assessment for the DNP project, a retrospective chart
review was conducted which revealed seven patients with a history of substance-related
disorders with no documentation of a risk assessment performed. After providing
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education to NP participants, risk assessments for opioid abuse was conducted on the 12
patients seen by the NP participants. Routine screening for anxiety/depression and
substance use disorders in primary care settings is imperative to mitigate risk for adverse
health outcomes (CDC, 2016). Although no opioids were prescribed by the NP
participants, known risks should be discussed will all patients prior to prescribing opioid
pain medication and patient and provider responsibilities should be outlined. Immediaterelease opioids should be prescribed at the lowest effective when starting
pharmacological therapy (CDC, 2016).
The prescription monitoring program (PMP) tracks prescribers who may be
prescribing opioids inappropriately (CMS, 2017a). Providers should review the PMP on
patients when starting opioid pain medications and periodically during treatment.
Experts suggest inappropriate prescribing contributes to misuse of prescription opioid
pain medication (Shapiro et al., 2013); therefore, NP participants were also instructed to
use the PMP for this project (CDC, 2016). The project did not evaluate whether the NPs
accessed and documented use of PMP in the medical record. Accessing the PMP and
other evidence-based practice guidelines should be followed when prescribing opioid
pain medications.
Implications for Theory
The conceptual framework used for this project is the SBIRT Program Matrix.
Participating NPs offered SBIRT services using the five components of the model at a
rural health primary care clinical site. The project director outlined program planning,
decision making, design, data collection and use during SBIRT program implementation.
Implementation outcomes of the SBIRT Program Matrix include but are not limited to
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program adoption, fidelity, costs, and grant compliance (Del Boca et al., 2017).
Recommendations for adoption of the SBIRT program at the practice site will need to
consider not only quality of care but costs and time in implementing SBIRT. Medicare,
Medicaid, and commercial insurance reimbursement billing codes exist for providers who
implement SBIRT (McCance-Katz & Satterfield, 2012; SAMHSA, 2016). With adoption
and implementation of SBIRT, documentation is also essential and SBIRT forms should
be scanned into the electronic medical record (EMR).
The fifth component of the SBIRT model, management structures and activities,
includes evidence-based protocols; coaching and staff evaluation; program evaluation
and dissemination; as well as facilitative administrative supports, systems interventions,
and sustainability planning as necessary components of SBIRT program implementation
and evaluation (Del Boca et al., 2017). Further evaluation of management structures and
activities is warranted. Initial evaluation of implementing the SBIRT model for this
project will be disseminated to stakeholders at the practice site where the project was
conducted and will be disseminated to interested audiences.
Policy Implications
Further efforts should address each component of the SBIRT matrix, especially in
the areas of coordination of care versus integration of care. Although SBIRT program
implementation is effective, patients currently receive care from multiple providers at
multiple practices sites making the process less seamless than desired. Nurse
practitioners can influence practice and policy to mitigate risk for abuse and misuse of
opioid pain medications. Utilizing an integrated care approach, dually certified NPs who
are family nurse practitioners (FNPs), as well as psychiatric mental health nurse
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practitioners (PMHNPs), are prepared to provide care to individuals with a pain
diagnoses and OUD with little to no fragmentation of care. Providers should offer or
arrange evidence-based treatment for patients with opioid use disorder (CDC, 2016).
Coordinated, co-located, and integrated care are three cores of
collaboration/integration encompassing six levels. Coordinated care is based on
communication involving minimal collaboration (Level 1) and basic collaboration at a
distance (Level 2) across separate facilities. Co-location focuses on physical proximity,
basic collaboration onsite (Level 3) and close collaboration onsite with some system
integration (Level 4). Integrated care requires a practice change aiming for close
collaboration approaching an integrated practice (Level 5) and full collaboration in
transformed/merged integrated practice (Level 6) (Heath, Wise, & Reynolds, 2013).
Screening and assessment vary at each level. Screening and assessment done per
separate practice models with separate treatment plans results in patients’ physical and
behavioral health needs being treated as separate issues. Although patients may be
referred, a variety of barriers prevent many patients from accessing care. Close
proximity allows referrals to be more successful and easier for patients. There is better
follow-up when patients are internally referred. Moreover, the integrated care team
approach feels like a one-stop shop. Patients experience a seamless response to all
healthcare needs in a unified practice (Heath et al., 2013). Community mental health
centers (CMHCs) and Federally Qualified Health Centers (FQHCs) are collaborating to
provide integrated primary and behavioral health services, including addiction services
(National Council for Behavioral Health, 2016). In the clinical setting where this DNP
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project was conducted, close collaboration onsite with system integration will meet the
needs of individuals with a pain diagnoses and opioid use disorder.
Medication-assisted treatment (MAT) is recommended for individuals diagnosed
with OUD. MAT, including opioid treatment programs (OPT), combines behavioral
therapy and medications in the treatment of substance use disorders.

Recent federal

legislation, the Comprehensive Addiction and Recovery Act (CARA), provisions include
increasing access to preventive services, medication-assisted treatment (MAT), and
recovery services. Nurse practitioners with the appropriate education and certification can
now be trained to treat OUD. NPs are granted privileges to prescribe buprenorphine in
community-based setting after completing training and receiving a waiver to prescribe
buprenorphine (SAMHSA, 2017). Since there are limited resources to refer patients for
treatment if identified as high risk for opioid abuse, developing an integrated care model
would be beneficial in providing care in one setting. NPs at the setting should keep
abreast of changes in federal and state laws regarding opioid use disorder prevention and
treatment so that qualified nurse practitioners are prepared to meet the need for
preventive services, MAT, and recovery services.
Recommendations for Future Evaluation
Screening tools for the assessment of potential risks of opioid therapy are helpful
for risk stratification. However, more screening studies are needed to explore outcomes
and should be expanded across the lifespan, adolescent to elderly. Tools with construct
partial validity include the Screener and Opioid Assessment for Patients with Pain
(SOAPP); the Opioid Risk Tool (ORT); and the Diagnosis, Intractability, Risk, and
Efficacy (DIRE) instrument. Regardless of the tool used by a provider, a thorough
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history is crucial to identify patients who require closer assessment, monitoring and or
referral (Claxton & Arnold, 2011). The strongest factor predictive of misuse after
initiation of opioid therapy is a personal or family history of alcohol or drug abuse.
Further evaluation is warranted specifically on the correlation of prescribing practices
and risk level identified via validated screening tools since researchers have revealed
patients may misuse after only being prescribed one prescription for opioid pain
medication (Levi, Segal, & Miller, 2013).
In addition, evaluation of risk for OUD in vulnerable and special populations such
as pregnant women are lacking. Most providers report being inadequately trained to
effectively treat pain and screen patients for prevention of misuse and abuse (The
Interagency Pain Research Coordinating Committee, 2015); therefore, outcome studies
that evaluate knowledge and implementation of evidence-based practices for prescribing
opioid pain medication should be conducted. Finally, further studies should be performed
to identify barriers to SBIRT implementation. Implementation outcomes of the SBIRT
framework are adoption; acceptability; appropriateness; feasibility; fidelity;
implementation costs; penetration; sustainability; service provision to at-risk populations;
and (if applicable) grant compliance (Del Boca et al., 2017). All components of the
SBIRT framework require further evaluation. NP participants for the DNP project voiced
concern regarding time constraints and costs. However, as mentioned previously, SBIRT
interventions are billable for commercial insurance, Medicare, and Medicaid. Again,
evaluation should be conducted to assess the cost of adopting, implementing, and
sustaining SBIRT and other evidence-based practice recommendations.
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Conclusions
Due to the epidemic stemming from misuse of opioid pain medications, the CDC
(2016) has implemented evidence-based guidelines to aid in risk mitigation.
Implementation of evidence-based guidelines promotes proper prescribing practices
which are directly correlated with patient risks (Katz et al., 2013). This DNP project was
carried out to evaluate if nurse practitioner providers are utilizing appropriate screening
to identify risk for opioid misuse in patients requesting opioid pain medications. Lowrisk levels for opioid pain medication misuse was identified among mostly young adults.
Young adults are an ideal population to implement interventions to mitigate risk
(SAMHSA, 2016). Project outcomes extend beyond improved patient outcomes but also
promote better-prescribing practices by NP providers. Implementing SBIRT in the
clinical setting conjunctly with other validated screening tools could prove to be quite
effective in combating misuse of opioid pain medication.
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APPENDIX A – Brief Negotiated Interview Algorithm
BRIEF NEGOTIATED INTERVIEW (BNI) ALGORITHM
1) BUILD RAPPORT Tell me about a typical day in your life.
Where does your current [X] use fit in?
Help me understand, through your eyes, the good things about
using [X]. What are some of the not‐so‐good things about
using [X]? So, on the one hand [PROS], and on the other hand
[CONS].
2) PROS & CONS Summarize I have some information on low‐
risk guidelines for drug use, would you mind if I shared them
with you? We know that use of illicit drugs such as
___
…can put you at risk for social or legal problems, as well as
illness and injury. It can also cause health problems like [insert
medical information]. What are your thoughts on that?
3) INFORMATION & FEEDBACK Elicit Provide Elicit This
Readiness Ruler is like the Pain Scale we use in the
hospital. On a scale from 1‐10, with 1 being not ready at all
and 10 being completely ready, how ready are you to change
your [X] use?
You marked ___. That’s great. That means
you are ___ % ready to make a change. Why did you choose that
number and not a lower one like a 1 or a 2?
4) READINESS RULER Reinforce positives Ask about lower #
5) ACTION PLAN Identify strengths & supports Write down
steps Offer appropriate resources. What are some steps/options
that will work for you to stay healthy and safe? What will help
you to reduce the things you don’t like about using [X]? What
supports do you have for making this change? Tell me about a
challenge you overcame in the past. How can you use those
supports/resources to help you now? Those are great ideas! Is it
okay for me to write down your plan, your own prescription for
change, to keep with you as a reminder? Will you summarize the
steps you’ll take to change your [X] use?
I have some additional resources that people sometimes find
helpful; would you like to hear about them? • Primary Care,
Outpatient counseling, Mental Health • Suboxone, Methadone
clinic, Needle Exchange, AA/NA, Smoking cessation • Shelter,
Insurance, Community Programs • Handouts and information
Thank patient Thank you for talking with me today.
BNI-ART Institute, www.bu.edu/bniart
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APPENDIX B –Review of Literature Table

Authors/
Year

Design/
Sample/
Setting

Framework/
Intervention/
Measures

American
Academy
of Pain
Medicine

American
Pain
Society

American
Society of
Addiction
Medicine
(ASAM)
(2016)

Guideline

Centers for Systematic
Disease
review
Control and
Prevention

Goal/
Aim

Outcomes/
Findings

Screening tools
to aid in
prevention

Reliable
instrument for
identifying
aberrant drugrelated
behaviors
could be
valuable for
ongoing
monitoring of
risks and
benefits of
chronic opioid
therapy

Treatment
approach to
prevent and treat
misuse/abuse

Recommends
coordination of
care when the
services of
other health
care
professionals
are needed
Recommends a
combination of
psychosocial
interventions
and
medications
for the
treatment of
opioid use
disorder.
12
recommendatio
ns for
management of
chronic pain

Coordination/int
egration of care

Analysis of
articles
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Promote better
opioid
prescribing
practices

(CDC)
(2016)
Chou et al
(2009)

Report of
8,034 abstracts
evidence by
expert panel
14
systematic
reviews; 57
primary
studies

Claxton &
Arnold
(2011)

Analysis of
articles

McCanceKatz &
Satterfield
(2012)

499,000
patients

Pathway to
prevention of
opioid
misuse/abuse

Integrate
prevention and
treatment of
substance abuse
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with opioid
pain
medication
Consideration
of the
effectiveness
of non-opioid
therapy should
precede
chronic opioid
therapy (COT).
Screening tools
for the
assessment of
potential risks
of COT are
helpful for risk
stratification.
Common
screening tools
for opioid
misuse in
patients with
chronic pain
are Screener
and Opioid
Assessment for
Pain Patients
(SOAPP) and
the Opioid
Risk Tool
(ORT).
A key to using
SBIRT in
primary care
settings
Utilizing the
SBIRT model,
there was a
67.7% decline
in reported
illicit drug use
at follow-up.

National
Institute on
Drug
Abuse
(2015)

To prevent
opioid use
disorder (OUD)

Paone,
Dowell,
Heller
(2011)

Report
City health
information

Reuben et
al
(2015)

National
Institute of
Health

Shapiro,
Coffa,
McCanceKatz
(2013)

Preventing
misuse of
prescription
opioid drugs

An effective
office-based
approach
includes a
coherent
framework for
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Overview of
opioid risk tool
(ORT) and its
validation in
screening for
opioid
misuse/abuse
To prevent
misuse
providers
should avoid
prescribing
opioids for
chronic pain
unless other
pharmacologic
al and or nonpharmacologic
al approaches
have been
ineffective.
Selection of
patients for an
opioid trial
should follow
weighing of
potential risks
and benefits of
COT.
Patients at
highest risk
should have
more
structured
monitoring
during followup visits at
regular
intervals.
Use of
motivational
rather than
confrontational
communication
is best during

identification of
risk to promote
behavioral
change

Substance
Abuse and
Mental
Health
Services
Administrat
ion
(SAMHSA
) (2016

Comprehensive,
integrated,
public health
approach
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screening,
counseling,
and treatment
to improve
patient
outcomes.
The SBIRT
initiative is a
comprehensive
approach used
in substance
abuse.

APPENDIX C –DNP Essentials
DNP Essentials

DNP Essentials and Competencies Met

DNP Essential I
Scientific underpinning for practice

Development, implementation, and
evaluation of new practice approaches
based on evidence-based clinical practice
guidelines (EBCP) and the SBIRT
conceptual framework was conducted for
the DNP project. The pilot integration of
the SBIRT program matrix framework
provides an understanding of the
conceptual model for program
implementation and evaluation.
Development and evaluation of a new
care approach met the current and future
needs of the organization, providers, and
patients. Accountability for quality health
care for the organization and patient
safety were met by educating nurse
practitioners regarding current EBCP
guidelines and validated tools to identify
and mitigate risk for opioid misuse and
abuse among patients.
Leadership skills were exemplified by the
project director functioning as a practice
specialist/consultant in a collaborative
evidence-guided practice. Information
technology and research methods were
used in the design and evaluation of the
project. Critical appraisal of the existing
scientific literature was conducted to
implement the best evidence for practice.
Translation of research into the practice
setting was implemented to improve
healthcare outcomes.
Utilization of information systems was
conducted during the need’s assessment to
evaluate outcomes of care and quality
improvement. Program design, selection,
use and an evaluation plan was developed
and executed to monitor outcomes of care,
including data abstraction. Information
systems/technology improvements in the

DNP Essential II
Organization and systems leadership
for quality improvement and systems
thinking

DNP Essential III
Clinical leadership and analytical
methods or evidence-based practice

DNP Essential IV
Information systems or technology
and patient care technology for the
improvement and transformation of
healthcare
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DNP Essential V
Health care policy for advocacy in
health care

DNP Essential VI
Inter-professional collaboration for
improving patient and population
health outcomes

DNP Essential VII
Clinical prevention and population
health for improving the nation’s
health

DNP Essential VIII
Advanced nursing practice

practice environment were recommended
upon evaluation of the DNP project.
Patient advocacy and leadership skills
were used in developing and
implementing health policies when
prescribing opioid pain medications. A
critical analysis of health policy and
related issues on prescription opioid pain
medication misuse/abuse at local, state,
and federal levels was conducted in
development and evaluation of the DNP
project.
Effective communication and
collaborative skills were utilized in the
development and implementation of the
DNP project. The project director led
interprofessional (medical director,
administrators, staff) and intraprofessional
(nurse practitioner) teams to create a
change in healthcare delivery.
Improvement of population health
outcomes was met through risk
identification in efforts to prevent and
reduce the risk for opioid misuse/abuse
among patients presenting to the primary
care clinic requesting a prescription for an
opioid pain medication.
Aggregate scientific data was analyzed
related to prescription opioid pain
medication misuse/abuse. Health
promotion/disease prevention efforts
focused on improvement of health status
and gaps in care for individuals at risk for
opioid misuse/abuse. The DNNP project
implemented guidelines and SBIRT to
prevent misuse and abuse of opioid pain
medications.
Conceptual and analytical skills were
utilized to evaluate the links among
practice, organization, population, fiscal,
and policy issues. Advanced levels of
clinical judgment, systems thinking, and
accountability were achieved in the
design, implementation, and evaluation of
evidence-based care to improve patient
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outcomes. The project director guided,
mentored, and supported other nurse
practitioners to achieve excellence in
nursing practice. A comprehensive and
systematic assessment of health and
illness parameters related to opioid
misuse/abuse in the practice setting was
conducted for the DNP project.
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APPENDIX D –Logic Model

INPUTS

Principal
investigator

OUTPUTS

ACTIVITIES

OUTCOMES

PARTICIPANTS

SHORT
TERM

MEDIUM
TERM

1)CDC
guideline
implementati
on

1)SBIRT
adoption at
multiple
sites

2)SBIRT
implementati
on

2)Better
prescribing
habits

LONG
TERM

EBP Guidelines
Stakeholders

Providers
SBIRT Training

SBIRT Tools
Implementation

Consultation

Patients
Administration
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1)Prevent
misuse/
abuse of
opioids
2)Prevention
of OUD
3)Decrease
healthcare
costs

APPENDIX E –Opioid Risk Tool (ORT)

OPIOID RISK TOOL
Mark each Item Score
Item Score box that applies
If Female

If Male

1. Family History of Substance Abuse Alcohol [ ]

1
Illegal Drugs [ ]
Prescription Drugs [ ]

2. Personal History of Substance Abuse Alcohol [ ]
Illegal Drugs [ ]
Prescription Drugs [ ]
3. Age (Mark box if 16 – 45) [ ]
4. History of Preadolescent Sexual Abuse [ ]
5. Psychological Disease Attention Deficit [ ]
Disorder,
Obsessive Compulsive
Disorder,
Bipolar,
Schizophrenia
Depression [ ]

3
2
4
3
4
5

3
4
3
4
5

1
3
2

1
0
2

1

1

TOTAL ––––––––––––
Total Score Risk Category
Low Risk 0 – 3
Moderate Risk 4 – 7
High Risk > 8
Reference: Webster LR. Predicting aberrant behaviors in opioid-treated patients: Preliminary
validation of the opioid risk tool. Pain Medicine. 2005;6(6):432-442. Used with permission.
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APPENDIX F – SBIRT Algorithm
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